-1.8%
CARR vs MRNA
+945.0%
-946.8%
-28.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | +13.1% | -12.6% | +0.4% |
| 7D | -0.7% | +20.6% | -21.3% | -0.8% |
| 30D | +0.3% | +27.1% | -26.8% | +0.1% |
| 3M | -14.9% | +353.4% | -368.3% | -16.9% |
| 6M | -14.9% | +446.3% | -461.1% | -19.5% |
| YTD | +7.0% | +776.2% | -769.2% | -4.4% |
| 1Y | -1.8% | +987.9% | -989.7% | -17.6% |
| All | -1.8% | +945.0% | -946.8% | -17.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling